Related Experiment Video

Updated: Mar 25, 2026

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.7K

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Jennie N Jeyapalan1,2, Veronika M Metzler1, Simone de Brot3

  • 1School of Veterinary Medicine and Sciences, University of Nottingham, Sutton Bonington, UK.

Molecular Oncology
|March 23, 2026
PubMed

Insights

Targeting lysine demethylase 7A (KDM7A) alongside KDM1A shows promise for advanced prostate cancer. Combination therapy inhibits the androgen receptor (AR) pathway, reducing cancer cell growth in castration-resistant prostate cancer (CRPC).

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Treatment resistance is a major challenge in advanced castration-resistant prostate cancer (CRPC), with limited curative options.
  • Epigenetic alterations, particularly lysine demethylases (KDMs), are implicated in cancer progression and resistance.
  • The role of KDM7A in prostate cancer (PCa) remains largely unexplored, despite its known role in other cancers.

Purpose of the Study:

  • To investigate the clinical relevance of KDM7A in prostate cancer, comparing it with the well-studied KDM1A.
  • To explore the potential of KDM7A as a therapeutic target in advanced prostate cancer.
  • To evaluate the efficacy of combination therapy targeting KDM1A and KDM7A in CRPC models.

Main Methods:

  • Utilized prostate cancer cell line models to study KDM7A function.
  • Confirmed KDM7A as an androgen receptor (AR) coregulator.
  • Employed commercially available pharmacological inhibitors for KDM1A and KDM7A in AR-positive CRPC cell lines.

Main Results:

  • KDM7A was confirmed as an AR coregulator in prostate cancer models.
  • Combined inhibition of KDM1A and KDM7A led to a significant loss of AR and AR-driven gene expression.
  • This combinatorial blockade attenuated cancer-promoting cell phenotypes in AR-positive CRPC cell lines.

Conclusions:

  • KDM7A plays a significant role in prostate cancer progression and AR signaling.
  • Combination therapy targeting KDM1A and KDM7A demonstrates potential for treating advanced prostate cancer.
  • Targeting epigenetic regulators offers a promising strategy for overcoming treatment resistance in CRPC.
Keywords:
Lysine demethylasesandrogen receptorcastration resistant prostate cancer (CRPC)co‐regulationepigeneticstherapeutics

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.1K
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K